Indivior PLC Notice of Results (6653R)
July 07 2022 - 9:00AM
UK Regulatory
TIDMINDV
RNS Number : 6653R
Indivior PLC
07 July 2022
Indivior to Announce Q2/H1 2022 Results and Host Webcast on July
28(th)
Slough, UK, and Richmond, VA, July 7, 2022 - Indivior PLC (LON:
INDV) today announced that it will release its Q2/H1 2022 results
on July 28(th) at 07:00 GMT (2:00 a.m. U.S. Eastern). The results
will be available via the London Stock Exchange's Regulatory News
Service (RNS) and on the "Investors" section of the company's
website at www.indivior.com .
Mark Crossley, Chief Executive Officer, and other members of
Indivior's leadership team will host a presentation via live
webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on July 28(th) .
Access to the Live Webcast Presentation
The webcast event and materials can be accessed on the
"Investors" section of the company's website at www.indivior.com
before the event begins.
The webcast link:
https://edge.media-server.com/mmc/p/n3frngii
Participants may access the presentation telephonically by
registering with the following link :
https://register.vevent.com/register/BI73d5563731f344dbbe611807e18a276d
(Please note this is a change from prior calls - registrants
will have an option to be called back directly immediately prior to
the call or be provided a call-in # with a unique pin code
following their registration)
A replay of the presentation will be available at
www.indivior.com .
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat substance
use disorders (SUD) and serious mental illnesses. Our vision is
that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs more than 900 individuals globally and its portfolio of
products is available in over 40 countries worldwide. Visit
www.indivior.com to learn more. Connect with Indivior on LinkedIn
by visiting www.linkedin.com/company/indivior .
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAPXXEEFAEEA
(END) Dow Jones Newswires
July 07, 2022 09:00 ET (13:00 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2023 to Apr 2024